Does EVEROLIMUS Cause Bladder transitional cell carcinoma? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Bladder transitional cell carcinoma have been filed in association with EVEROLIMUS (EVEROLIMUS). This represents 0.0% of all adverse event reports for EVEROLIMUS.
7
Reports of Bladder transitional cell carcinoma with EVEROLIMUS
0.0%
of all EVEROLIMUS reports
0
Deaths
0
Hospitalizations
How Dangerous Is Bladder transitional cell carcinoma From EVEROLIMUS?
Of the 7 reports.
Is Bladder transitional cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVEROLIMUS. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does EVEROLIMUS Cause?
Death (5,090)
Malignant neoplasm progression (3,789)
Diarrhoea (3,061)
Fatigue (2,946)
Stomatitis (2,692)
Nausea (2,079)
Dyspnoea (1,925)
Drug ineffective (1,837)
Pyrexia (1,664)
Decreased appetite (1,633)
What Other Drugs Cause Bladder transitional cell carcinoma?
PIOGLITAZONE (398)
ADALIMUMAB (96)
METHOTREXATE (95)
RITUXIMAB (74)
TOCILIZUMAB (68)
INFLIXIMAB (63)
SULFASALAZINE (55)
HYDROXYCHLOROQUINE (50)
PREDNISONE (48)
LENALIDOMIDE (42)
Which EVEROLIMUS Alternatives Have Lower Bladder transitional cell carcinoma Risk?
EVEROLIMUS vs EVOLOCUMAB
EVEROLIMUS vs EXELON
EVEROLIMUS vs EXEMESTANE
EVEROLIMUS vs EXENATIDE
EVEROLIMUS vs EXFORGE